Related Experiment Videos
[What is reliable in therapy of liver fibrosis?]
1Medizinische Klinik und Poliklinik B, Westfälischen Wilhelms-Universität, Münster.
Abstract:
Therapy of chronic active liver diseases associated with fibrotic transformation is usually restricted to unspecific antiinflammatory and immunosuppressive agents. However, recent advances in the biochemistry of collagen have allowed to define specific levels of collagen metabolism at which pharmacologic intervention can lead to reduced collagen deposition. The mode of action of some substances which interfere with collagen biosynthesis and degradation is described. However, the efficacy of these agents was tested in vitro exclusively or in animal experiments. Only few agents like colchicine were also studied in clinical trials. Reliable, safe, and specific antifibrotic agents for the clinical management of liver fibrosis do not exist up to now. Advances can be expected, however, from the development of novel inhibitors of prolyl-4-hydroxylase.
Insights
Current liver fibrosis treatments lack specificity. Novel prolyl-4-hydroxylase inhibitors show promise for developing targeted antifibrotic therapies for chronic liver diseases.
Area of Science:
- Biochemistry
- Pharmacology
- Hepatology
Context:
- Chronic active liver diseases often involve fibrotic transformation.
- Current therapies rely on non-specific anti-inflammatory and immunosuppressive agents.
- Limited options exist for effective antifibrotic interventions in liver fibrosis.
Purpose:
- To review advances in understanding collagen metabolism for targeted antifibrotic drug development.
- To discuss substances interfering with collagen biosynthesis and degradation.
- To highlight the need for reliable and specific antifibrotic agents.
Summary:
- Recent biochemical insights into collagen metabolism offer potential for pharmacologic intervention.
- Substances affecting collagen synthesis and breakdown have been explored, primarily in vitro and in animal models.
- Clinical efficacy of antifibrotic agents remains limited, with colchicine being an exception studied in trials.
Impact:
- Development of novel prolyl-4-hydroxylase inhibitors represents a significant advancement.
- Future therapies may offer specific and effective treatments for liver fibrosis.
- Targeted antifibrotic agents could improve clinical management of chronic liver diseases.